Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
PROPOFOL
PFIZER CANADA ULC
N01AX10
PROPOFOL
10MG
EMULSION
PROPOFOL 10MG
INTRAVENOUS
20ML
Prescription
MISCELLANEOUS GENERAL ANESTHETICS
Active ingredient group (AIG) number: 0121833001; AHFS:
CANCELLED POST MARKET
2020-02-24
_Product Monograph – _ _Pr_ _Propofol-II Injection _ _ _ _Page 1 of 54_ _ _ PRODUCT MONOGRAPH PR PROPOFOL-II INJECTION 1% w/v propofol injection 10 mg/mL Pfizer Standard Intravenous Emulsion – Anaesthetic - Sedative Pfizer Canada Inc. 17300 Trans-Canada Highway Kirkland, Québec H9J 2M5 Date of Revision: October 2, 2018 Submission Control No.: 219498 _Product Monograph – _ _Pr_ _Propofol-II Injection _ _ _ _Page 2 of 54_ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ...................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................... 3 CONTRAINDICATIONS ................................................................................................. 4 WARNINGS AND PRECAUTIONS ............................................................................... 5 ADVERSE REACTIONS ............................................................................................... 10 DRUG INTERACTIONS ............................................................................................... 15 DOSAGE AND ADMINISTRATION ........................................................................... 15 OVERDOSAGE .............................................................................................................. 24 ACTIONS AND CLINICAL PHARMACOLOGY........................................................ 24 STORAGE AND STABILITY ....................................................................................... 28 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................... 28 PART II: SCIENTIFIC INFORMATION ............................................................................. 29 PHARMACEUTICAL INFORMATION ....................................................................... 29 DETAILED PHARMACOLOGY ..................................................................... Baca dokumen lengkapnya